EP0891353A1 - Inhibiteurs de farnesyle-proteine transferase - Google Patents

Inhibiteurs de farnesyle-proteine transferase

Info

Publication number
EP0891353A1
EP0891353A1 EP97917669A EP97917669A EP0891353A1 EP 0891353 A1 EP0891353 A1 EP 0891353A1 EP 97917669 A EP97917669 A EP 97917669A EP 97917669 A EP97917669 A EP 97917669A EP 0891353 A1 EP0891353 A1 EP 0891353A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
aryl
hydrogen
independently selected
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97917669A
Other languages
German (de)
English (en)
Other versions
EP0891353A4 (fr
Inventor
Christopher J. Dinsmore
Theresa M. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616736.6A external-priority patent/GB9616736D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0891353A1 publication Critical patent/EP0891353A1/fr
Publication of EP0891353A4 publication Critical patent/EP0891353A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • Ras proteins are part of a signalling pathway that links cell surface growth factor receptors to nuclear signals initiating cellular proliferation.
  • Biological and biochemical studies of Ras action indicate that Ras functions like a G-regulatory protein.
  • Ras In the inactive state, Ras is bound to GDP.
  • Ras Upon growth factor receptor activation Ras is induced to exchange GDP for GTP and undergoes a conformational change.
  • the GTP-bound form of Ras propagates the growth stimulatory signal until the signal is terminated by the intrinsic GTPase activity of Ras, which returns the protein to its inactive GDP bound form (D.R. Lowy and D.M.
  • Mutated ras genes (Ha-ras, Ki4a-ras, Ki4b-ras and N-ras) are found in many human cancers, including colorectal carcinoma, exocrine pancreatic carcinoma, and myeloid leukemias. The protein products of these genes are defective in their GTPase activity and constitutively transmit a growth stimulatory signal.
  • Ras must be localized to the plasma membrane for both normal and oncogenic functions. At least 3 post-translational modifications are involved with Ras membrane localization, and all 3 modifications occur at the C-terminus of Ras.
  • the Ras C-terminus contains a sequence motif termed a "CAAX” or "Cys-Aaa 1 -Aaa ⁇ -Xaa” box (Cys is cysteine, Aaa is an aliphatic amino acid, the Xaa is any amino acid) (Willumsen et al, Nature 570:583-586 (1984)).
  • this motif serves as a signal sequence for the enzymes famesyl-protein transferase or geranylgeranyl-protein transferase, which catalyze the alkylation of the cysteine residue of the CAAX motif with a C15 or C20 isoprenoid, respectively.
  • the Ras protein is one of several proteins that are known to undergo post-translational famesylation. 9 -
  • farnesylated proteins include the Ras-related GTP-binding proteins such as Rho, fungal mating factors, the nuclear lamins, and the gamma subunit of transducin. James, et al., J. Bi ⁇ l. Chem. 269, 14182 (1994) have identified a peroxisome associated protein Pxf which is also farnesylated. James, et al., have also suggested that there are farnesylated proteins of unknown stmcture and function in addition to those listed above.
  • Famesyl-protein transferase utilizes famesyl pyrophosphate to covalently modify the Cys thiol group of the Ras CAAX box with a famesyl group (Reiss et al., Cell, 62:81-88 (1990); Schaber et al., J. Biol. Chem., 265: 14701 -14704 (1990); Schafer et al., Science, 249: 1133-1139 (1990); Marine et al., Proc. Natl. Acad. Sci USA, 87:7541 -7545 (1990)).
  • Inhibition of famesyl pyrophosphate biosynthesis by inhibiting HMG-CoA reductase blocks Ras membrane localization in cultured cells.
  • direct inhibition of famesyl- protein transferase would be more specific and attended by fewer side effects than would occur with the required dose of a general inhibitor of isoprene biosynthesis.
  • FPTase famesyl-protein transferase
  • FPP famesyl diphosphate
  • Ras protein substrates
  • the peptide derived inhibitors that have been described are generally cysteine containing molecules that are related to the CAAX motif that is the signal for protein prenylation.
  • Such inhibitors may inhibit protein prenylation while serving as alternate substrates for the famesyl-protein transferase enzyme, or may be purely competitive inhibitors (U.S. Patent 5,141 ,851 , University of Texas; N.E. Kohl et al, Science, 260: 1934-1937 (1993); Graham, et al., /. Med. Chem., 37, 725 (1994)).
  • deletion of the thiol from a CAAX derivative has been shown to dramatically reduce the inhibitory potency of the compound.
  • the thiol group potentially places limitations on the therapeutic application of FPTase inhibitors with respect to pharmacokinetics, pharmacodynamics and toxicity. Therefore, a functional replacement for the thiol is desirable.
  • famesyl-protein transferase inhibitors are inhibitors of proliferation of vascular smooth muscle cells and are therefore useful in the prevention and thereapy of arteriosclerosis and diabetic disturbance of blood vessels (JP H7- 112930).
  • an object of this invention to develop peptidomimetic compounds that do not have a thiol moiety, and that will inhibit famesyl-protein transferase and thus, the post-translational famesylation of proteins. It is a further object of this invention to develop chemotherapeutic compositions containing the compounds of this invention and methods for producing the compounds of this invention.
  • the present invention comprises small molecule imidazolidinone-containing compounds which inhibit the famesyl- protein transferase.
  • the instant compounds lack a thiol moiety and thus offer unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol -dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity.
  • chemotherapeutic compositions containing these famesyl transferase inhibitors and methods for their production are further contained in this invention.
  • the compounds of this invention are useful in the inhibition of famesyl-protein transferase and the famesylation of the oncogene protein Ras.
  • the inhibitors of famesyl-protein transferase are illustrated by the formula I:
  • R la, Rib nd R2 are independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C10 cycloalkyl, C2-C6 alkenyl, C2- C6 alkynyl, R 8 0-, R9S(0) m -, R8C(0)NR 8 -, CN, N ⁇ 2, (R8)2N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, N3, -N(R 8 )2, or R9 ⁇ C(0)NR8-, c) C1 -C6 alkyl unsubstituted or substituted by aryl, heterocyclic, C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, R 0-, R 9 S(0) m -, R c(0)NR8-, CN, (R 8 )2N- C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, N3, -N(R
  • R 3 and R 4 are independently selected from F, Cl, Br, N(R 8 )2, CF3, N02, (R8)0-, (R9)S(0)m-, (R 8 )C(0)NH-, H2N- C(NH)-, (R8)C(0)-, (R8)OC(0)-, N3, CN, CF3(CH2)nO-, (R9)OC(0)NR8-, C1 -C2O alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycle;
  • R6 is independently selected from: a) hydrogen, b) aryl, heterocycle, C3-C 10 cycloalkyl, C2-C6 alkenyl, C2-
  • R7 is attached to a substitutable carbon on W and is selected from: a) hydrogen, b) C2-C6 alkenyl, C2-C6 alkynyl, perfluoroalkyl, F, Cl, Br, R 0-, R9S(0) m -, R 8 C(0)NR8-, CN, N02,
  • R is independently selected from hydrogen, C1-C6 alkyl, benzyl and aryl;
  • R9 is independently selected from C1 -C6 alkyl and aryl
  • R 10 and R are independently selected from: H; ° or
  • V is selected from: a) hydrogen, b) heterocycle, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, provided that V is not hydrogen if A is S(0)m and V is not hydrogen if Al is a bond, n is 0 and A 2 is S(0)m;
  • W is a heterocycle
  • Y is aryl or heteroaryl
  • n 0, 1 , 2, 3 or 4
  • p 0, 1 , 2, 3 or 4
  • q 0, 1 , 2, 3 or 4
  • r 0 to 5, provided that r is 0 when V is hydrogen; and t is O or l;
  • Rl and R2 are independently selected from: hydrogen or C i -C6 alkyl
  • Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 8 0-, -N(R8)2 or C2-C6 alkenyl, c) Cl-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R ⁇ -, or -N(R 8 )2;
  • R 3 and R 4 are independently selected from F, Cl, Br, N(R 8 )2, CF3, N02, (R8)0-, (R9)S(0) m -, (R 8 )C(0)NH-, H2N-
  • R° is independently selected from: a) hydrogen, b) C1 -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1 -C6 perfluoroalkyl, F, Cl, R 8 0-, R C(0)NR8-, CN, N ⁇ 2, (R8)2N-C(NR8)-, R 8 C(0)-, R80C(0)-, -N(R 8 )2, or
  • R90C(0)NR8- and c) C1-C6 alkyl substituted by C1-C6 perfluoroalkyl, R 8 0-, R8C(0)NR8-, (R8) 2 N-C(NR8)-, R8C(0)-, R 8 OC(0)-, -N(R8)2, or R9 ⁇ C(0)NR8-;
  • R ⁇ is hydrogen or methyl
  • R8 is independently selected from hydrogen, -C6 alkyl, benzyl and aryl;
  • R9 is independently selected from C1-C alkyl and aryl
  • R 10 and RU are independently selected from: H; O or
  • V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C1-C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S. and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if A is S(0)m and V is not hydrogen if A 1 is a bond, n is 0 and A2 is S(0)m;
  • n 0, 1, 2, 3 or 4
  • p 0, 1 , 2, 3 or 4
  • q 0, 1 , 2, 3 or 4
  • r 0 to 5, provided that r is 0 when V is hydrogen;
  • Rla and R2 are independently selected from: hydrogen or C] -C6 alkyl
  • Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 8 0-, -N(R8)2 or C2-C6 alkenyl, c) C1 -C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R 0-, or -N(R 8 )2:
  • R 3 and R 4 are independently selected from F, Cl, Br, N(R 8 )2, CF3, N02, (R 8 )0-, (R9)S(0) m -, (R8)C(0)NH-, H2N- C(NH)-, (R8)C(0)-, (R 8 )OC(0)-, N3, CN, (R9)OC(0)NR8-, C 1 -C20 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycle;
  • R° is independently selected from: a) hydrogen, b) Cl -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C ] -C6 perfluoroalkyl, F, Cl, R s O-, R8C(0)NR8-, CN, N ⁇ 2, (R8)2N-C(NR8)_, R8C(0)-, R8 ⁇ C(0)-, -N(R 8 )2, or R9 ⁇ C(0)NR8-, and c) C1 -C6 alkyl substituted by -C6 perfluoroalkyl, R 8 0-,
  • R7 is selected from: hydrogen and C1 -C6 alkyl
  • R is independently selected from hydrogen, Cl -C ⁇ alkyl, benzyl and aryl;
  • R is independently selected from C1-C6 alkyl and aryl
  • RlO and RU are independently selected from: H; or
  • Ci-5 alkyl unbranched or branched, unsubstituted or substituted with one or more of: 1 ) aryl, 2) heterocycle,
  • V is selected from: a) hydrogen, b) heterocycle selected from pyrrolidinyl, imidazolyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, isoquinolinyl, and thienyl, c) aryl, d) C1 -C20 alkyl wherein from 0 to 4 carbon atoms are replaced with a a heteroatom selected from O, S, and N, and e) C2-C20 alkenyl, and provided that V is not hydrogen if Al is S(0) m and V is not hydrogen if A l is a bond, n is 0 and A2 is S(0) ;
  • W is a heterocycle selected from pyrrolidinyl, pyridinyl, thiazolyl, pyridonyl, 2-oxopiperidinyl, indolyl, quinolinyl, or isoquinolinyl;
  • n 0, 1 , 2, 3 or 4
  • p 0, 1 , 2, 3 or 4
  • q 0, 1 , 2, 3 or 4
  • r is 0 to 5, provided that r is 0 when V is hydrogen: and t is 1 ;
  • the inhibitors of famesyl-protein transferase are illustrated by the formula Ic:
  • Rib is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R 8 0-, -N(R 8 )2 or C2-C6 alkenyl, c) C1-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R8O-, or -N(R 8 )2;
  • R2 are independently selected from: hydrogen or C1-C6 alkyl
  • R 3 and R 4 are independently selected from F, Cl, Br, N(R 8 )2, CF3, N02, (R 8 )0-, (R9)S(0) m -, (R8)C(0)NH-, H2N-
  • R° is independently selected from: a) hydrogen, b) Cl -C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, Cl -C6 perfluoroalkyl, F, Cl, R80-, R8C(0)NR 8 -, CN, NO2, (R8)2N-C(NR8)-, R8c(0)-, R 8 OC(0)-, -N(R8)2, or
  • R9OC(0)NR8. and c) C1-C6 alkyl substituted by C1 -C6 perfluoroalkyl, R 8 0-, R8C(0)NR8-, (R8) N-C(NR8)-, R8C(0)-, R8 ⁇ C(0)-, -N(R8)2, or R9 ⁇ C(0)NR8- ;
  • R is independently selected from hydrogen, C1-C alkyl, benzyl and aryl;
  • R9 is independently selected from C1-C alkyl and aryl
  • Ri is independently selected from: a) hydrogen, b) aryl, heterocycle, cycloalkyl, R8 ⁇ -, -N(R 8 )2 or C2-C6 alkenyl, c) Cl-C6 alkyl unsubstituted or substituted by aryl, heterocycle, cycloalkyl, alkenyl, R8 ⁇ -, or -N(R8)2;
  • R2 are independently selected from: hydrogen or Cl-C6 alkyl
  • R 3 and R 4 are independently selected from F, Cl, Br, N(R 8 )2, CF3, N02, (R8)0-, (R9)S(0)m-, (R )C(0)NH-, H2N- C(NH)-, (R8)C(0)-, (R8)OC(0)-, N3, CN, (R9)0C(0)NR8-, C1 -C20 alkyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocycle;
  • R 8 is independently selected from hydrogen, C1 -C alkyl, benzyl and aryl;
  • R is independently selected from C1 -C6 alkyl and aryl; NR a t
  • R ib and RU are independently selected from: H; O or
  • C ⁇ _5 alkyl unbranched or branched, unsubstituted or substituted with one or more of:
  • the compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention.
  • any variable e.g. aryl, heterocycle, Rl , R2 e tc.
  • Rl aryl, heterocycle, Rl , R2 e tc.
  • alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms; “alkoxy” represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge.
  • Halogen or “halo” as used herein means fluoro, chloro, bromo and iodo.
  • aryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of such aryl elements include phenyl, naphthyl, tetrahydronaphthyl, indanyl, biphenyl, phenanthryl, anthryl or acenaphthyl.
  • heterocycle or heterocyclic represents a stable 5- to 7-membered monocyclic or stable 8- to 1 1 - membered bicyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl,
  • heteroaryl is intended to mean any stable monocyclic or bicyclic carbon ring of up to 7 members in each ring, wherein at least one ring is aromatic and wherein from one to four carbon atoms are replaced by heteroatoms selected from the group consisting of N, O, and S.
  • heterocyclic elements include, but are not limited to, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothiopyranyl sulfone, furyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxadiazolyl, pyridyl, pyrazinyl, pyrazolyl, pyridazinyl, pyrimidinyl, pyrrolyl, quinazolin
  • substituted aryl As used herein, the terms “substituted aryl”, “substituted heterocycle” and “substituted cycloalkyl” are intended to include the cyclic group which is substituted with 1 or 2 substitutents selected from the group which includes but is not limited to F, Cl, Br, CF3, NH2, N(Cl -C6 alkyl)2, N ⁇ 2, CN, (C1-C6 alkyl)0-, -OH, (C1 -C6 alkyl)S(0) m -, (C1-C6 alkyl)C(0)NH-, H2N-C(NH)-, (Ci -C ⁇ alkyl)C(O)-, (C1-C6 alkyl)OC(O)-, N3 C1-C6 alkyl)OC(0)NH- and C1 -C20 alkyl.
  • nitrogen protecting group is as described in U.S. Patent No. 5,424,328 and includes those groups usually employed in the chemistry of peptides, typically a triphenylmethyl, t-butyloxycarbonyl, acetyl, formyl, di(p- methoxyphenyl)methyl and (p-methoxyphenyl)diphenylmethyl.
  • Lines drawn into the ring systems from substituents indicate that the indicated bond may be attached to any of the substitutable ring carbon atoms.
  • Rla, Rib nd R2 a re independently selected from: hydrogen, -N(R8)2, R8C(0)NR8- or C1 -C6 alkyl unsubstituted or substituted by -N(R8)2, R80- or R8c(0)NR8-.
  • R 3 and R 4 are independently selected from: hydrogen, perfluoroalkyl, F, Cl, Br, R80-, R 9 S(0)m-, CN, NO2, R8 2 N-C(NR8)-, R8c(0)-, R8 ⁇ C(0)-, N3, -N(R8)2, or R9 ⁇ C(0)NR 8 - and Cl -C6 alkyl.
  • R6 is selected from: hydrogen, perfluoroalkyl,
  • R? is hydrogen.
  • R 8 is selected from H, C1 -C6 alkyl and benzyl.
  • R9 is selected from C] -C6 alkyl.
  • RlO and R l 1 is selected from H, Cl -C ⁇ alkyl and benzyl.
  • a 1 and A are independently selected from: a bond, -C(0)NR 8 -, -NR 8 C(0)-, O, -N(R 8 )-, -S(0)2N(R 8 )- and- N(R 8 )S(0)2-.
  • V is selected from hydrogen, heterocycle and aryl. Most preferably, V is phenyl.
  • Y is selected from phenyl, furyl, thienyl and pyridyl. Most preferably, Y is phenyl.
  • n, p and r are independently 0, 1 , or 2.
  • t is 1.
  • the substituent (R6) r - V - Al (CRla2) n A (CR l a2) n - is not H, Q -C6 alkyl or a nitrogen protecting group;
  • the pharmaceutically acceptable salts of the compounds of this invention include die conventional non-toxic salts of the compounds of this invention as formed, e.g., from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like: and d e salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxy-benzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, trifluoroacetic and the like.
  • -N(R8)2 represents -NHH, -NHCH3, -NHC2H5, etc. It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials.
  • the pharmaceutically acceptable salts of the compounds of this invention can be synthesized from the compounds of this invention which contain a basic moiety by conventional chemical methods.
  • the salts are prepared either by ion exchange chromatography or by reacting the free base with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid in a suitable solvent or various combinations of solvents.
  • Reactions used to generate the compounds of this invention are prepared by employing reactions as shown in Schemes 1 -13, in addition to other standard manipulations such as ester hydrolysis, cleavage of protecting groups, etc., as may be known in the literature or exemplified in the experimental procedures.
  • Substituents R and R CH2- as shown in the Schemes, represent the substituents R8, R and others, depending on the compound of the instant invention that is being synthesized.
  • the variable p' represents p-1.
  • Schemes 1 -4 illustrates the synthesis of one of the preferred embodiments of the instant invention, wherein the variable W is present as a imidazolyl moiety that is substituted with a suitably substituted benzyl group.
  • Substituted protected imidazole alkanols II can be prepared by methods known in the art, such as those described by F. Schneider, Z. Physiol. Chem., 3:206-210 (1961) and C.P. Stewart, Biochem. Journal, 17:130-133(1923).
  • Scheme 3 illustrates the synthesis of an aldehyde Via which corresponds to aldehyde VI but which has an unsaturated R 10/R 1 1 moiety. Subsequent reactions provide the instant compound XII.
  • the compound XVI is isolated in the salt form, for example, as a trifluoroacetate, hydrochloride or acetate salt, among others.
  • Compound XVI can further be selectively protected to obtain XVII which can subsequently be reductively alkylated with a second aldehyde, such as XVIII, to obtain intermediate XIX.
  • a second aldehyde such as XVIII
  • Removal of the protecting group, and conversion to cyclized products such as the dihydroimidazole XX can be accomplished by literature procedures, such as those shown.
  • the product XXII can be reacted with triphosgene to form the imidazolidinone ring and the protecting groups can be subsequently removed to unmask the hydroxyl group (Schemes 1 1 , 12).
  • the alcohol can be oxidized under standard conditions to e.g. an aldehyde, which can then be reacted with a variety of organometallic reagents such as Grignard reagents, to obtain secondary alcohols such as XXIV.
  • the fully deprotected amino alcohol XXV can be reductively alkylated (under conditions described previously) with a variety of aldehydes to obtain secondary amines, such as XXVI (Scheme 12), or tertiary amines.
  • the Boc protected amino alcohol XXIII can also be utilized to synthesize 2-aziridinylmethylamides such as XX VII (Scheme 13). Treating XXIII with l ,l '-sulfonyldiimidazole and sodium hydride in a solvent such as dimethylformamide leads to the formation of aziridine XXVII.
  • the aziridine may be reacted with a nucleophile, such as a thiol, in the presence of base to yield, after deprotection, the ring- opened product XXVin.
  • the diamine XIII can be reacted with aldehydes derived from amino acids such as O-alkylated tyrosines, according to standard procedures, to obtain compounds such as XXXII, as shown in Scheme 14.
  • Intermediate XXXII is first reacted with triphosgene to form the imidazolidinone ring before it is further elaborated.
  • R' is an aryl group
  • XXXIII can first be hydrogenated to unmask the phenol, and the amine group deprotected with acid to produce XXXIV.
  • the amine protecting group in XXXIII can be removed, and O-alkylated phenolic amines such as XXXV produced.
  • the instant compounds are useful as pharmaceutical agents for mammals, especially for humans. These compounds may be administered to patients for use in the treatment of cancer.
  • Examples of the type of cancer which may be treated with the compounds of this invention include, but are not limited to, colorectal carcinoma, exocrine pancreatic carcinoma, myeloid leukemias and neurological tumors. Such tumors may arise by mutations in the ras genes themselves, mutations in the proteins that can regulate Ras formation (i.e., neurofibromen (NF-1 ), neu, scr, abl , lck, fyn) or by other mechanisms.
  • the compounds of the instant invention inhibit famesyl- protein transferase and the famesylation of the oncogene protein Ras.
  • the instant compounds may also inhibit tumor angiogenisis, thereby affecting the growth of tumors (J. Rak et al. Cancer Research, 55:4575- 4580 (1995)). Such anti-angiogenisis properties of the instant compounds may also be useful in the treatment of certain forms of blindness related to retinal vascularization.
  • the compounds of this invention are also useful for inhibiting other proliferative diseases, both benign and malignant, wherein Ras proteins are aberrantly activated as a result of oncogenic mutation in other genes (i.e., the Ras gene itself is not activated by mutation to an oncogenic form) with said inhibition being accomplished by the administration of an effective amount of the compounds of the invention to a mammal in need of such treatment.
  • a component of NF- 1 is a benign proliferative disorder.
  • the instant compounds may also be useful in the treatment of certain viral infections, in particular in the treatment of hepatitis delta and related viruses (J.S. Glenn et al. Science, 256: 1331 - 1333 (1992).
  • the compounds of the instant invention are also useful in the prevention of restenosis after percutaneous transluminal coronary angioplasty by inhibiting neointimal formation (C. Indolfi et al. Nature medicine, 1 :541 -545(1995).
  • the instant compounds may also be useful in the treatment and prevention of polycystic kidney disease (D.L. Schaffner et al. American Journal of Pathology, 142: 1051 -1060 (1993) and B. Cowley, Jr. et ⁇ X.FASEB Journal, 2:A3160 (1988)).
  • the compounds of this invention may be administered to mammals, preferably humans, either alone or, preferably, in combination with pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice.
  • the compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
  • the selected compound may be administered, for example, in the form of tablets or capsules, or as an aqueous solution or suspension.
  • carriers which are commonly used include lactose and corn starch, and lubricating agents, such as magnesium stearate, are commonly added.
  • useful diluents include lactose and dried com starch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring agents may be added.
  • sterile solutions of the active ingredient are usually prepared, and the pH of the solutions should be suitably adjusted and buffered.
  • the total concentration of solutes should be controlled in order to render the preparation isotonic.
  • the present invention also encompasses a pharmaceutical composition useful in the treatment of cancer, comprising the administration of a therapeutical ly effective amount of the compounds of this invention, with or without pharmaceutically acceptable carriers or diluents.
  • suitable compositions of this invention include aqueous solutions comprising compounds of this invention and pharmacolo ⁇ gically acceptable carriers, e.g., saline, at a pH level, e.g., 7.4.
  • the solutions may be introduced into a patient's intramuscular blood-stream by local bolus injection.
  • the daily dosage will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual patient, as well as the severity of the patient's symptoms.
  • a suitable amount of compound is administered to a mammal undergoing treatment for cancer.
  • Administration occurs in an amount between about 0.1 mg/kg of body weight to about 60 mg/kg of body weight per day, preferably of between 0.5 mg/kg of body weight to about 40 mg/kg of body weight per day.
  • the compounds of the instant invention are also useful as a component in an assay to rapidly determine the presence and quantity of famesyl-protein transferase (FPTase) in a composition.
  • FPTase famesyl-protein transferase
  • the composition to be tested may be divided and the two portions contacted with mixtures which comprise a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and famesyl pyrophosphate and, in one of the mixtures, a compound of the instant invention.
  • the chemical content of the assay mixtures may be determined by well known immunological, radiochemical or chromatographic techniques. Because the compounds of the instant invention are selective inhibitors of FPTase, absence or quantitative reduction of the amount of substrate in the assay mixture without the compound of the instant invention relative to the presence of the unchanged substrate in the assay containing the instant compound is indicative of the presence of FPTase in the composition to be tested. It would be readily apparent to one of ordinary skill in the art that such an assay as described above would be useful in identifying tissue samples which contain famesyl-protein transferase and quantitating the enzyme.
  • potent inhibitor compounds of the instant invention may be used in an active site titration assay to determine the quantity of enzyme in the sample.
  • a series of samples composed of aliquots of a tissue extract containing an unknown amount of famesyl-protein transferase, an excess amount of a known substrate of FPTase (for example a tetrapeptide having a cysteine at the amine terminus) and famesyl pyrophosphate are incubated for an appropriate period of time in the presence of varying concentrations of a compound of the instant invention.
  • concentration of a sufficiently potent inhibitor i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel
  • concentration of a sufficiently potent inhibitor i.e., one that has a Ki substantially smaller than the concentration of enzyme in the assay vessel
  • Step A Preparation of l -triphenylmethyl-4-(hydroxymethyl)- imidazole
  • Step B Preparation of l -triphenylmethyl-4-(acetoxymethyl)- imidazole
  • Step C Preparation of l-(4-cyanobenzyl)-5-(acetoxymethyl)- imidazole hydrobromide
  • Step D Preparation of l-(4-cyanobenzyl)-5-(hydroxymethyl)- imidazole .
  • Step E Preparation of l -(4-cyanobenzyl)-5-imidazole- carboxaldehyde
  • Step F Preparation of l-(methanesulfonyl)-2-butyne
  • Step G Preparation of ( ⁇ )-ethyl 2-[(phenylmethyl)imino]-4- hexynoate
  • Step H Preparation of ( ⁇ )-ethyl 2-[(? -butoxycarbonyl)amino]-4- hexynoate A solution of the product from Step G (ca. 51.8 mmol) was stirred at room temperature in 5% aqueous HCI solution ( 100 mL).
  • Step I Preparation of ( ⁇ )-2-[(r ⁇ ?rt-butoxycarbonyl)amino]-4- hexynoic acid
  • Step K Preparation of ( ⁇ )-2-(r ⁇ ?r -butoxycarbonylamino)-4-hexynal
  • a suspension of lithium aluminum hydride (1.56 g, 41.1 mmol) in ether (150 mL) was stirred at room temperature for 30 minutes.
  • the solution was cooled to -55 °C under nitrogen, and a solution of the product from Step J (11.10 g, 41.1 mmol) in ether (150 mL) was added over 15 min, maintaining the temperature below -50 °C.
  • the reaction was warmed to 5 °C, then recooled to -40 °C.
  • a solution of potassium hydrogen sulfate (21.8 g) in 25 mL water was slowly added, maintaining the temperature below -35 °C.
  • Step M Preparation of ( ⁇ )-2-[(l -(4-cyanobenzyl)-5- imidazolylmethyl)amino]-l-[(3-chlorophenyl)amino]-4- hexyne
  • a solution of the product from Step L (2.74 g, 8.51 mmol) in 15 mL of dichloromethane was added at 0 °C dropwise 7 mL of trifluoroacetic acid. The reaction was allowed to gradually warm to room temperature. After 4 hours, the solution was concentrated in vacuo. The resulting product was partitioned between dilute aqueous NaHC ⁇ 3 solution and dichloromethane.
  • Step N Preparation of ( ⁇ )-4-(2-butynyl)-l-(3-chlorophenyl)-3-[ l - (4-cyanobenzyl)-5-imidazolylmethyl]-2-imidazolidinone hydrochloride
  • triethylamine 0.12 mL, 0.89 mmol
  • triphosgene 26 mg, 0.088 mmol
  • Step A /V-Methoxy-/V-methyl 2(S)-( ⁇ rr-butoxycarbonylamino)- hexanamide
  • Step B 2(S)-(rer/-Butoxycarbonylamino)hexanal
  • Step C /V-(2,3-Dimethylphenyl)-2(S)-( rf- butoxycarbonylamino hexanamine
  • 2,3-Dimethylaniline (8.32 mL, 68.3 mmol) was dissolved in dichloroethane under nitrogen. Acetic acid was added to obtain pH 5, and sodium triacetoxyborohydride (17.2 g, 80.8 mmol) and crushed molecular sieves (4 g) were added.
  • a solution of the product from Step B (13.3 g, 62.1 mmol) in dichloroethane (80 mL) was added slowly dropwise at 20°C. The reaction was stirred overnight, then quenched with saturated sodium bicarbonate solution. The aqueous layer was removed, the organic phase washed with saturated brine and dried over magnesium sulfate. Crystallization from hexane gave the title compound.
  • Step D Preparation of (S)-2-f(l-(4-cyanobenzyl)-5- imidazolylmethyl)amino]-l-[(2,3-dimethylphenyl)amino]-4- hexane
  • Step E Preparation of (S)-4-/z-butyl-3-[l -(4-cyanobenzyl)-5- imidazolylmethyl]- 1 -(2,3-dimethylphenyl)-2- imidazolidinone hydrochloride
  • the product was taken up in methanol and injected onto a preparative HPLC column and purified with a mixed gradient of 25%- 55% acetonitrile/0.1 % TFA; 75%-45% 0.1 % aqueous TFA over 50 minutes. After concentration in vacuo, the resultant product was partitioned between dichloromethane and aq. NaHC ⁇ soln., and the aqueous phase was extracted with CH 2 CI 2 . The organic solution was washed with brine, dried (Na 2 S0 4 ), filtered, and concentrated to dryness to provide the product free base, which was taken up in CH 2 CI 2 and treated with excess 1 M HCl/ether solution. After concentrated in vacuo, the titled product (33.7 mg) was isolated as a white powder.
  • Step B Preparation of / -f l-(4-cyanobenzyl)-5-imidazolylmethyl]- y (3_cillpJ ⁇ ghOTy ⁇ JeJh J ⁇ ne ⁇
  • the amine hydrochloride from Step A (978 mg) was partitioned between dilute aqueous NaHC ⁇ 3 solution and methylene chloride. The aqueous layer was washed with three portions of CH2CI2, and the combined organics were dried (Na2S ⁇ 4), filtered, and concentrated in vacuo to provide the free amine.
  • the aldehyde from Step E of Example 1 (1.21 g) was added, and the reaction was stirred at 0 °C.
  • Step C Preparation of l -(3-chlorophenyl)-3-[ l -(4-cyanobenzyl)-5- imidazolylmethyll-2-imidazolidinone hydrochloride
  • Step A Preparation of (S)-2-[(4-chloro-l -(4-cyanobenzyl)-5- imidazolylmemyl)amino]-l -[(2-chloro-5,6- dimethylphenyl)aminol-4-hexane hydrochloride
  • the product was taken up in methanol and injected onto a preparative HPLC column and purified with a mixed gradient of 25%-55% acetonitrile/0.1 % TFA; 75%-45% 0.1 % aqueous TFA over 50 minutes. After concentration in vacuo, the resultant product was partitioned between dichloromethane and aq. NaHC ⁇ soln., and the aqueous phase was extracted with CH 2 CI 2 . The organic solution was washed with brine, dried (Na 2 S0 4 ), filtered, and concentrated to dryness to provide the product free base, which was taken up in CH 2 CI 2 and treated with excess 1 M HCl/ether solution. After concentrated in vacuo, the titled product was isolated as a white powder.
  • Step B Preparation of 4-(S)-4- «-butyl-3-[ 4-chloro- 1 -(4- cyanobenzyl)-5-imidazolylmethyl]- 1 -(2-chloro-5,6- dimethylphenyl)-2-imidazolidinone hydrochloride
  • the product was purified by silica gel chromatography (2.5-5% MeOH/CH 2 Cl2), then taken up in CH 2 CI 2 and treated with excess 1 M HCl/ether solution. After concentrated in vacuo, the titled product ( 18 mg) was isolated as a white powder.
  • Step A Preparation of (S)-2-( rt-butoxycarbonylamino)-N- methoxy- ⁇ -methyl-4-(methylthio)butanamide
  • Step B Preparation of (S)-2-(t(?rf-butoxycarbonylamino)-N- methoxy-N-methyl-4-(methanesulfonyl)butanamide
  • Step D Preparation of (S)-2-(/ -butoxycarbonylamino)-N-(3- chlorobenzyl)-4-(methanesulfonyl)butanamine
  • 3-chlorobenzylamine 0.628 mL, 5.14 mmol
  • crushed molecular sieves 1.5 g
  • sodium triacetoxyborohydride 2.73 g, 12.9 mmol
  • the reaction was stirred ovemight, allowing it to warm to room temperature.
  • Step E Preparation of (S)-2-(ferf-butoxycarbonylamino)-N- (benzyloxycarbonyl)-N-(3-chlorobenzyl)-4- (methanesulfonyl)butanamine
  • benzylchloroformate (0.303 mL, 2.12 mmol).
  • Step F Preparation of (S)-2-[(l -(4-cyanobenzyl)-5- imidazolylmethyl)ammo]-N-(berizyloxycarbonyl)-N-(3- chlorobenzyl)-4-(methanesulfonyl)butanamine
  • Step G Preparation of (S)-2-[(l -(4-cyanobenzyl)-5- imidazolylmethyl)amino]-./V-(3-chlorobenzyl)-4-
  • Step H Preparation of (S)- 1 -(3-chlorobenzyl)-3-[ 1 -(4- cyanobenzyl)-5-imidazolylmethyl]-4-[(2- methanesulfonyl)ethyll-2-imidazolidinone hydrochloride
  • triethylamine 0.1 mL, 1.0 mmol
  • triphosgene 31 mg, 0.10 mmol
  • Bovine FPTase was assayed in a volume of 100 ⁇ l containing 100 mM N-(2- hydroxy ethyl) piperazine-/V'-(2-ethane sulfonic acid) (HEPES), pH 7.4, 5 mM MgCl2, 5 mM dithiothreitol (DTT), 100 mM [ H]-farnesyl diphosphate ([3HJ-FPP; 740 CBq/mmol, New England Nuclear), 650 nM Ras-CVLS and 10 ⁇ g/ml FPTase at 31 °C for 60 min. Reactions were initiated with FPTase and stopped with 1 ml of 1.0 M HCL in ethanol.
  • Precipitates were collected onto filter-mats using a TomTec Mach II cell harvestor, washed with 100% ethanol, dried and counted in an LKB ⁇ - plate counter.
  • the assay was linear with respect to both substrates, FPTase levels and time; less than 10% of the [ ⁇ HJ-FPP was utilized during the reaction period.
  • Purified compounds were dissolved in 100% dimethyl sulfoxide (DMSO) and were diluted 20-fold into the assay. Percentage inhibition is measured by the amount of incorporation of radioactivity in the presence of the test compound when compared to the amount of incorporation in the absence of the test compound.
  • DMSO dimethyl sulfoxide
  • Human FPTase was prepared as described by Omer et aL, Biochemistry 32:5167-5176 (1993). Human FPTase activity was assayed as described above with the exception that 0.1 % (w/v) polyethylene glycol 20,000, 10 ⁇ M ZnCl 2 and 100 ⁇ M Ras-CVIM were added to the reaction mixture. Reactions were performed for 30 min., stopped with 100 ⁇ l of 30% (v/v) trichloroacetic acid (TCA) in ethanol and processed as described above for the bovine enzyme. The compound of the instant invention described hereinabove in Example 1 was tested for inhibitory activity against human FPTase by the assay described above and was found to have IC50 of ⁇ 10 ⁇ M.
  • the cell line used in this assay is a v-ras line derived from either Ratl or NIH3T3 cells, which expressed viral Ha-ras p21.
  • the assay is performed essentially as described in DeClue, J.E. et a , Cancer Research 51 :712-717, (1991). Cells in 10 cm dishes at 50-75% confluency are treated with the test compound (final concentration of solvent, methanol or dimethyl sulfoxide, is 0.1%).
  • the cells After 4 hours at 37°C, the cells are labelled in 3 ml methionine-free DMEM supple- meted with 10% regular DMEM, 2% fetal bovine serum and 400 mCi[35S]methionine (1000 Ci/mmol). After an additional 20 hours, the cells are lysed in 1 ml lysis buffer (1 % NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF) and the lysates cleared by centrifugation at 100,000 x g for 45 min.
  • 1 ml lysis buffer (1 % NP40/20 mM HEPES, pH 7.5/5 mM MgCl2/lmM DTT/10 mg/ml aprotinen/2 mg/ml leupeptin/2 mg/ml antipain/0.5 mM PMSF
  • the immunoprecipitates are washed four times with IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1 % Triton X- 100.0.5% deoxycholate/0.1 %/SDS/0.1 M NaCl) boiled in SDS-PAGE sample buffer and loaded on 13% acrylamide gels. When the dye front reached the bottom, the gel is fixed, soaked in Enlightening, dried and autoradiographed. The intensities of the bands corresponding to farnesylated and nonfarnesylated ras proteins are compared to determine the percent inhibition of famesyl transfer to protein.
  • IP buffer (20 nM HEPES, pH 7.5/1 mM EDTA/1 % Triton X- 100.0.5% deoxycholate/0.1 %/SDS/0.1 M NaCl
  • Rat 1 cells transformed with either v-ras, v-raf, or v-mos are seeded at a density of 1 x 10 4 cells per plate (35 mm in diameter) in a 0.3% top agarose layer in medium A (Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum) over a bottom agarose layer (0.6%). Both layers contain 0.1 % methanol or an appropriate concentration of the instant compound (dissolved in methanol at 1000 times the final concentration used in the assay).
  • the cells are fed twice weekly with 0.5 ml of medium A containing 0.1 % methanol or the concentration of the instant compound. Photomicrographs are taken 16 days after the cultures are seeded and comparisons are made.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés inhibant la farnésyle-protéine transférase (FTase) ainsi que la farnésylation de la protéine Raz oncogène. L'invention concerne également des compositions chimiothérapeutiques contenant les composés de ladite invention ainsi que des méthodes inhibant la farnésyle-protéine transférase et la farnésylation de la protéine Ras oncogène.
EP97917669A 1996-04-03 1997-03-27 Inhibiteurs de farnesyle-proteine transferase Withdrawn EP0891353A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1477796P 1996-04-03 1996-04-03
US14777P 1996-04-03
GBGB9616736.6A GB9616736D0 (en) 1996-07-09 1996-07-09 Inhibitors of farnesyl-protein transferase
GB9616736 1996-08-09
PCT/US1997/005060 WO1997036892A1 (fr) 1996-04-03 1997-03-27 Inhibiteurs de farnesyle-proteine transferase

Publications (2)

Publication Number Publication Date
EP0891353A1 true EP0891353A1 (fr) 1999-01-20
EP0891353A4 EP0891353A4 (fr) 2001-08-08

Family

ID=26309841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917669A Withdrawn EP0891353A4 (fr) 1996-04-03 1997-03-27 Inhibiteurs de farnesyle-proteine transferase

Country Status (5)

Country Link
EP (1) EP0891353A4 (fr)
JP (1) JP2000507581A (fr)
AU (1) AU716153B2 (fr)
CA (1) CA2250192A1 (fr)
WO (1) WO1997036892A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027752A1 (fr) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
US6297239B1 (en) * 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
PT1058683E (pt) * 1998-02-02 2003-04-30 Lg Chemical Ltd Inibidores da farnesil-transferase com uma estrutura de piperidina e seu processo de preparacao
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
US7129359B2 (en) 2002-07-09 2006-10-31 National Health Research Institutes Imidazolidinone compounds
US7259174B2 (en) 2004-05-25 2007-08-21 National Health Research Institutes Imidazolidinone compounds
CA2655574A1 (fr) 2006-06-20 2007-12-27 Wyeth Inhibiteurs du canal potassique kv1-5
US8637560B2 (en) 2007-07-18 2014-01-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
WO2011069039A1 (fr) 2009-12-04 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composés d'hydrazone et de diacylhydrazine, et leurs procédés d'utilisation
JP2014040374A (ja) * 2010-12-15 2014-03-06 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害物質

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009001A1 (fr) * 1993-09-30 1995-04-06 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase
WO1995025092A1 (fr) * 1994-03-14 1995-09-21 Merck & Co., Inc. Inhibiteurs de la proteine farnesyl-transferase
WO1996010034A2 (fr) * 1994-09-29 1996-04-04 Merck & Co., Inc. Inhibiteurs de la transferase de proteines farnesylees exempts de thiol
WO1996030343A1 (fr) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3020276A (en) * 1958-03-03 1962-02-06 Petrolite Corp Cyclic amidines
US4661602A (en) * 1985-03-29 1987-04-28 G. D. Searle & Co. Substituted alkyl imidazole derivatives
US4810800A (en) * 1986-05-06 1989-03-07 Merrell Dow Pharmaceuticals Inc. Novel imidazole dopamine beta hydroxylase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009001A1 (fr) * 1993-09-30 1995-04-06 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase
WO1995025092A1 (fr) * 1994-03-14 1995-09-21 Merck & Co., Inc. Inhibiteurs de la proteine farnesyl-transferase
WO1996010034A2 (fr) * 1994-09-29 1996-04-04 Merck & Co., Inc. Inhibiteurs de la transferase de proteines farnesylees exempts de thiol
WO1996030343A1 (fr) * 1995-03-29 1996-10-03 Merck & Co., Inc. Inhibiteurs de farnesyl-proteine transferase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRAHAM,S.L.: "Inhibitors of protein farnesylation : a new approach to cancer chemotherapy" EXP.OPIN.THER.PATENTS, vol. 5, no. 12, December 1995 (1995-12), pages 1269-1285, XP001000610 LONDON *
See also references of WO9736892A1 *
WILLIAMS T M ET AL: "COMMUNICATIONS TO THE EDITOR. N-ARYLPIPERAZINONE INHIBITORS OF FARNESYLTRANSFERASE: DISCOVERY AND BIOLOGICAL ACTIVITY" JOURNAL OF MEDICINAL CHEMISTRY,AMERICAN CHEMICAL SOCIETY. WASHINGTON,US, vol. 42, 1999, pages 3779-3784, XP000941686 ISSN: 0022-2623 *

Also Published As

Publication number Publication date
EP0891353A4 (fr) 2001-08-08
JP2000507581A (ja) 2000-06-20
WO1997036892A1 (fr) 1997-10-09
CA2250192A1 (fr) 1997-10-09
AU716153B2 (en) 2000-02-17
AU2593297A (en) 1997-10-22

Similar Documents

Publication Publication Date Title
AU704087B2 (en) Inhibitors of farnesyl-protein transferase
US6066738A (en) Inhibitors of farnesyl-protein transferase
US5968965A (en) Inhibitors of farnesyl-protein transferase
WO1997036889A1 (fr) Inhibiteurs de farnesyle-proteine transferase
US5780492A (en) Inhibitors of farnesyl-protein transferase
EP0891360A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
AU715667B2 (en) Inhibitors of farnesyl-protein transferase
AU712504B2 (en) Inhibitors of farnesyl-protein transferase
EP0891357A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
EP0891343A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
AU707416B2 (en) Inhibitors of farnesyl-protein transferase
EP0891352A1 (fr) Inhibiteurs de la farnesyl-proteine transferase
AU716153B2 (en) Inhibitors of farnesyl-protein transferase
WO1996034010A2 (fr) Inhibiteurs de la farnesyle transferase
AU703988B2 (en) Inhibitors of farnesyl-protein transferase
US5972984A (en) Inhibitors of farnesyl-protein transferase
US6028201A (en) Inhibitors of farnesyl-protein transferase
EP0935464A1 (fr) Inhibiteurs de transferase de farnesyl-proteine
EP0959883A1 (fr) Inhibiteurs de la farnesyle-proteine transferase
US5981562A (en) Inhibitors of farnesyl-protein transferase
EP0900081A1 (fr) Inhibiteurs de farnesyl-proteine transferase
WO1996031525A2 (fr) Inhibiteurs de la farnesyl-proteine transferase
AU5428596A (en) Inhibitors of farnesyl-protein transferase
EP0837857A2 (fr) Inhibiteurs de la farnesyl-proteine transferase
CA2243320A1 (fr) Inhibiteurs de la farnesyle transferase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19981103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010622

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

18D Application deemed to be withdrawn

Effective date: 20010911